 |
Postmenopausal Systemic Hormone Therapy: Reaching Consensus at Last on Benefit and Risk CME/CE Author Information and Disclosures Release Date: June 30, 2008; Valid for credit through June 30, 2009 | Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.0 NPWH contact hours (1 contact hour is in the area of pharmacology) | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME/CE Activity- Postmenopausal Systemic Hormone Therapy: Reaching Consensus at Last on Benefit and RiskHoward N. Hodis, MD; Rogerio A. Lobo, MD; Cynthia A. Stuenkel, MD; Wulf H. Utian, MD, PhD, DSc(Med)Available As: Slides/Video | Slides/Transcript
Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Comments made during this program are individual opinions and not necessarily the view of The North American Menopause Society (NAMS), the National Association of Nurse Practitioners in Women's Health (NPWH), or Medscape. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - List menopause-related symptoms and related health risks.
- Review the current scientific literature regarding the benefits and risks of various systemic menopausal hormone therapy (HT) treatment options.
- Select women who are candidates for
systemic HT.
- Explain the most effective ways to communicate the potential benefit-risk ratio of systemic HT to individual patients.
- Apply this information in clinical practice with the goal of providing optimal quality of life for women at menopause and beyond.
Authors and Disclosures |
 |
|
The North American Menopause Society (NAMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NAMS designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Each individual should only claim credit commensurate with the extent of their participation in the educational activity.
|
 |
|
Approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women's Health.
This activity has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women’s Health (NPWH) for 1 contact hour of continuing education credit, including 1 hour of pharmacology content. Each participant should claim only those contact hours that he/she actually spent in the educational activity.
Participants should only claim credit commensurate with the extent of
their participation in the activity.
|
|
